USPTO serial 88830893
UNLEARN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 6, 2020
- Examiner
- MONDELL, DOUGLAS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with UNLEARN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $850
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Francisco, CA, US
San Francisco, CA, US
San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Isaac M. Fine
Isaac M. Fine KPPB LLP180 E. Ocean Blvd., Suite 1030Long Beach, CA 90802United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | business consulting and management in the fields of medical research, pharmaceutical development and clinical trials for business purposes; business consulting and management in the field of clinical trials, namely, management and compilation of computerized databases in the field of clinical trials for business purposes; business consulting and management in the field of pharmaceutical development, namely, management and compilation of computerized databases in the field of pharmaceutical development for business purposes; business consulting and management in the field of pharmaceutical development, namely, management and compilation of computerized databases in the field of medical research for business purposes | ACTIVE | — |
| 042 | providing medical and scientific research information in the fields of medical research, pharmaceutical development and clinical trials; consulting services for others in the field of design and planning of clinical trials; consulting services for others in the fields of medical research and pharmaceutical development; consulting services for others in the fields of medical research and pharmaceutical development, namely, providing digital models of patients for use as simulated control subjects; consulting services for others in the field of design and planning of clinical trials, namely, providing digital models of patients for use as simulated control subjects for clinical trials; providing data analytics and artificial intelligence in the nature of providing temporary use of online non-downloadable software for use in the design and planning of clinical trials; providing data analytics and artificial intelligence in the nature of providing temporary use of online non-downloadable software for use in medical research and pharmaceutical development; providing data analytics and artificial intelligence in the nature of providing temporary use of online non-downloadable software for use in the life sciences field for the purpose of research, development, and commercialization; providing temporary use of on-line non-downloadable cloud computing software for managing, gathering, generating, organizing, and sharing data in the fields of pharmaceutical development, medical clinical trials and medical research; providing temporary use of on-line non-downloadable cloud computing software for designing, managing, and executing medical clinical trials and medical research and medical clinical trial and medical research protocols; providing temporary use of on-line non-downloadable cloud computing software for designing, managing, and executing pharmaceutical development research; providing a website featuring educational information in the fields of medical research, pharmaceutical development, clinical trials and artificial intelligence | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 21, 2026 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Dec 12, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 12, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 12, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 6, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Apr 22, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 22, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 22, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 22, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 17, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Apr 17, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 17, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 17, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 23, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 23, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 23, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 23, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 23, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 6, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 21, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 16, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 12, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 11, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 8, 2020 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jun 8, 2020 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Jun 8, 2020 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Jun 8, 2020 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Jun 2, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 18, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 14, 2020 | NWAP | NEW APPLICATION ENTERED | — |